PLK4 and atherosclerosis: In sum, our study has demonstrated that CFI-400945, an anticancer drug that inhibits PLK4, significantly blocks intimal hyperplasia of mouse carotid arteries but increases atherosclerosis in vivo and the underlying mechanism may involve the induction of SMC polyploidization and subsequent apoptosis.